SINGAPORE – Across much of Asia, and in China in particular, the responsibility of fighting for the rights of rare disease patients mostly falls on the shoulders of patient themselves. By talking with the government and industry, patient groups are pushing for more effective drug development and orphan drug discovery policies. Unfortunately, once disease conditions and cultural elements are taken into account, those groups may have significant challenges ahead.